Stockscreener 앱 받기
0.3161
3.29%
-0.0089
전일 마감가:
$0.325
열려 있는:
$0.3183
하루 거래량:
126.13K
Relative Volume:
0.44
시가총액:
$12.05M
수익:
$7.88M
순이익/손실:
$-69.20M
주가수익비율:
-0.1727
EPS:
-1.83
순현금흐름:
$-69.73M
1주 성능:
+7.27%
1개월 성능:
-15.51%
6개월 성능:
-45.68%
1년 성능:
-59.42%
1일 변동 폭
$0.31
$0.3183
1주일 범위
$0.295
$0.4624
52주 변동 폭
$0.2895
$0.81
볼트 바이오테라퓨틱스 Stock (BOLT) Company Profile
명칭
Bolt Biotherapeutics Inc
전화
650-665-9295
주소
900 CHESAPEAKE DRIVE, REDWOOD CITY
BOLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.3143 | 12.15M | 7.88M | -69.20M | -69.73M | -1.83 |
|
ONC
Beigene Ltd Adr
|
241.88 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.95 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.82 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.95 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
볼트 바이오테라퓨틱스 Stock (BOLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 개시 | Guggenheim | Buy |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
볼트 바이오테라퓨틱스 주식(BOLT)의 최신 뉴스
Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Lake Street Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy Recommendation - Nasdaq
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics wit - GuruFocus
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics with Buy Rating | BOLT Stock News - GuruFocus
Lake Street Begins Coverage of Bolt Biotherapeutics (BOLT) with Bullish Outlook | BOLT Stock News - GuruFocus
Leerink Partnrs Has Optimistic Outlook of BOLT Q2 Earnings - Defense World
Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00 - Defense World
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates - MSN
BOLT Stock Target Price Revised to $1 Amid Recent Developments | - GuruFocus
BOLT: Stifel Lowers Price Target on Bolt Biotherapeutics, Mainta - GuruFocus
Bolt Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
BOLT Exceeds Q1 Revenue Expectations with Higher Earnings | BOLT Stock News - GuruFocus
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - San Antonio Express-News
Bolt Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bolt Biotherapeutics Inc (BOLT) Q1 2025 Earnings: EPS of -$0.29 - GuruFocus
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
BOLT: Surge in Interest for Bolt Biotherapeutics Amid Key Develo - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study an - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study and Financial Updates | BOLT Stock News - GuruFocus
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - The Manila Times
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 ... - Eagle-Tribune
Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia
Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus
Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India
Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq
Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan
Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada
Bolt Biotherapeutics modifies quorum requirements - Investing.com
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World
Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World
볼트 바이오테라퓨틱스 (BOLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
자본화:
|
볼륨(24시간):